Global Anxiety and Panic Disorders Drugs Market 2017-2021

About Anxiety and Panic Disorders Drugs
Anxiety is a normal reaction to stress, which helps to deal with tense situations. However, when anxiety becomes an excessive and irrational extension of everyday situations, it turns into disorder as per medical definition. Panic attacks, a type of anxiety disorder, are associated with sudden episodes of emotions of fear and anxiety.

Technavio’s analysts forecast the global anxiety and panic disorders drugs market to grow at a CAGR of 1.78 % during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global anxiety and panic disorders drugs market for 2017-2021. To calculate the market size, the report considers the sales from both branded and generic drugs.

The market is divided into the following segments based on geography:
‧ Americas
‧ APAC
‧ EMEA

Technavio's report, Global Anxiety and Panic Disorders Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
‧ AstraZeneca
‧ Eli Lilly
‧ GlaxoSmithKline
‧ Pfizer
Other prominent vendors
‧ Azevan Pharmaceuticals
‧ Baxter
‧ Bristol-Myers Squibb
‧ F. Hoffman-La Roche
Market driver
‧ Increasing stress in day-to-day life
‧ For a full, detailed list, view our report

Market challenge
‧ Availability of electroceuticals
‧ For a full, detailed list, view our report

Market trend
‧ Synergistic effects of medication aided with neuromodulation devices
‧ For a full, detailed list, view our report

Key questions answered in this report
‧ What will the market size be in 2021 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
‧ Key market highlights
PART 05: Disease overview
PART 06: Pipeline analysis
PART 07: Market landscape
‧ Market overview
‧ Market size and forecast
‧ Five forces analysis
PART 08: Market segmentation by drug class
‧ Antidepressant drugs market
‧ Anxiolytic drugs market
‧ Others
PART 09: Geographical segmentation
‧ Anxiety and panic disorders drugs market in Americas
‧ Anxiety and panic disorders drugs market in EMEA
‧ Anxiety and panic disorders drugs market in APAC
PART 10: Decision framework
PART 11: Drivers and challenges
‧ Market drivers
‧ Impact of drivers on key customer segments
‧ Market challenges
‧ Impact of challenges on key customer segments
PART 12: Market trends
‧ Synergistic effects of medication aided with neuromodulation devices
‧ Growing public awareness
‧ Evolving scientist’s interest for development of novel therapeutics
PART 13: Vendor landscape
‧ Competitive scenario
PART 14: Key vendor analysis
‧ AstraZeneca
‧ Eli Lilly
‧ GlaxoSmithKline
‧ Pfizer
‧ Other prominent vendors
PART 15: Appendix
‧ List of abbreviations
List of Exhibits
Exhibit 01: Management of anxiety and panic disorder
Exhibit 02: Key marketed products for the treatment of anxiety and panic disorders
Exhibit 03: Pipeline snapshot based on drug class
Exhibit 04: Pipeline snapshot based on mechanism of action
Exhibit 05: Pipeline snapshot based on vendors
Exhibit 06: Pipeline trends
Exhibit 07: Key clinical trials
Exhibit 08: Global anxiety and panic disorders drugs market snapshot
Exhibit 09: Global anxiety and panic disorders drugs market 2016-2021 ($ millions)
Exhibit 10: Opportunity analysis in global anxiety and panic disorders drugs market
Exhibit 11: Five forces analysis
Exhibit 12: Market segmentation based on drug class
Exhibit 13: Market segmentation based on drug class 2016 (%)
Exhibit 14: Global anxiety and panic disorder antidepressant drugs market 2016-2021 ($ millions)
Exhibit 15: Global anxiety and panic disorders anxiolytic drugs market 2016-2021 ($ millions)
Exhibit 16: Global anxiety and panic disorders drugs market of other drug classes 2016-2021 ($ millions)
Exhibit 17: Segmentation of global anxiety and panic disorders drugs market based on geography 2016 and 2021
Exhibit 18: Global anxiety and panic disorders drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 19: Market scenario in America
Exhibit 20: Anxiety and panic disorders drugs market in Americas 2016-2021 ($ millions)
Exhibit 21: Market scenario in EMEA
Exhibit 22: Anxiety and panic disorders drugs market in EMEA 2016-2021 ($ millions)
Exhibit 23: Market scenario in APAC
Exhibit 24: Anxiety and panic disorders drugs market in APAC 2016-2021 ($ millions)
Exhibit 25: Impact of drivers
Exhibit 26: Impact of challenges
Exhibit 27: Competitive structure analysis of global anxiety and panic disorders drugs market 2016
Exhibit 28: AstraZeneca: Key highlights
Exhibit 29: AstraZeneca: Strength assessment
Exhibit 30: AstraZeneca: Strategy assessment
Exhibit 31: AstraZeneca: Opportunity assessment
Exhibit 32: Eli Lilly: Key highlights
Exhibit 33: Eli Lilly: Strength assessment
Exhibit 34: Eli Lilly: Strategy assessment
Exhibit 35: Eli Lilly: Opportunity assessment
Exhibit 36: GlaxoSmithKline: Key highlights
Exhibit 37: GlaxoSmithKline: Strength assessment
Exhibit 38: GlaxoSmithKline: Strategy assessment
Exhibit 39: GlaxoSmithKline: Opportunity assessment
Exhibit 40: Pfizer: key highlights
Exhibit 41: Pfizer: Strength assessment
Exhibit 42: Pfizer: Strategy assessment
Exhibit 43: Pfizer: Opportunity assessment